原发性肾移植后 1 年以上巨细胞病毒感染的影响。
The impact of cytomegalovirus infection ≥1 year after primary renal transplantation.
机构信息
Transplant Services, Balboa Nephrology Medical Group, Inc., San Diego, CA, USA.
出版信息
Clin Transplant. 2010 Jul-Aug;24(4):572-7. doi: 10.1111/j.1399-0012.2010.01208.x.
Abstract
We studied the impact of a first post-transplant cytomegalovirus (CMV) infection greater than one year after primary kidney transplantation. Risk factors for developing late CMV were acute rejection and donor-recipient CMV status. Of those developing late CMV, 35% were donor (D) positive, recipient (R) negative; however, 23% were D+R+, 22% D-R+, and 15% D-R-. Late CMV was associated with significantly decreased patient and graft survival.
摘要
我们研究了原发性肾移植后一年以上初次移植后巨细胞病毒（CMV）感染的影响。发生晚期 CMV 的危险因素是急性排斥反应和供受者 CMV 状态。在发生晚期 CMV 的患者中，35%为供体（D）阳性，受体（R）阴性；然而，23%为 D+R+，22%为 D-R+，15%为 D-R-。晚期 CMV 与患者和移植物存活率显著降低相关。
相似文献
1
The impact of cytomegalovirus infection ≥1 year after primary renal transplantation.原发性肾移植后 1 年以上巨细胞病毒感染的影响。
Clin Transplant. 2010 Jul-Aug;24(4):572-7. doi: 10.1111/j.1399-0012.2010.01208.x.
2
Clinical outcome with low-dose valacyclovir in high-risk renal transplant recipients: a 10-year experience.低剂量伐昔洛韦在高危肾移植受者中的临床疗效：10 年经验。
Nephrol Dial Transplant. 2013 Mar;28(3):758-65. doi: 10.1093/ndt/gfs531. Epub 2012 Dec 14.
3
The impact of early cytomegalovirus infection after kidney transplantation on long-term graft and patient survival.肾移植后早期巨细胞病毒感染对移植肾长期存活及患者生存的影响。
Clin Transplant. 2014 Jan;28(1):120-6. doi: 10.1111/ctr.12288. Epub 2013 Dec 18.
4
Cytomegalovirus mismatch still negatively affects patient and graft survival in the era of routine prophylactic and preemptive therapy: A paired kidney analysis.巨细胞病毒错配仍会影响常规预防和抢先治疗时代的患者和移植物存活率：配对肾脏分析。
Am J Transplant. 2019 Feb;19(2):573-584. doi: 10.1111/ajt.15183. Epub 2018 Dec 14.
5
Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.对高风险（供体巨细胞病毒血清学阳性、受体巨细胞病毒血清学阴性）肾移植受者进行抢先抗巨细胞病毒治疗。
Int J Infect Dis. 2017 Dec;65:50-56. doi: 10.1016/j.ijid.2017.09.023. Epub 2017 Oct 3.
6
Cytomegalovirus infection post-pancreas-kidney transplantation--results of antiviral prophylaxis in high-risk patients.巨细胞病毒感染胰腺-肾移植术后——高危患者抗病毒预防的结果。
Clin Transplant. 2013 Jul-Aug;27(4):503-9. doi: 10.1111/ctr.12138. Epub 2013 Jun 3.
7
Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.巨细胞病毒血清学状态配对和抗病毒预防的成年受者中死亡供体肾移植结局。
Transplantation. 2010 Nov 27;90(10):1091-8. doi: 10.1097/TP.0b013e3181f7c053.
8
Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival.早期巨细胞病毒感染及疾病对长期受者及肾移植存活的影响。
Kidney Int. 2004 Jul;66(1):329-37. doi: 10.1111/j.1523-1755.2004.00735.x.
9
Revisiting cytomegalovirus serostatus and replication as risk factors for inferior long-term outcomes in the current era of renal transplantation.重新探讨巨细胞病毒血清学状态和复制作为当前肾移植时代长期预后不良的风险因素。
Nephrol Dial Transplant. 2020 Feb 1;35(2):346-356. doi: 10.1093/ndt/gfz268.
10
Acute rejection episodes in pediatric renal transplant recipients with cytomegalovirus infection.患有巨细胞病毒感染的小儿肾移植受者的急性排斥反应发作
Pediatr Transplant. 2008 Jun;12(4):474-8. doi: 10.1111/j.1399-3046.2007.00781.x.
引用本文的文献
1
Bridging the gap: assessing CMV DNAemia in kidney transplant recipients with previous solid organ transplants.弥合差距：评估曾接受实体器官移植的肾移植受者的巨细胞病毒血症。
Front Transplant. 2024 Apr 9;3:1280280. doi: 10.3389/frtra.2024.1280280. eCollection 2024.
2
A Decade-Long Cohort Analysis of Human Cytomegalovirus (HCMV)-Induced Early and Late Renal Rejection in Post-Transplant Patients in the Eastern Indian Population.一项针对东印度人群移植后患者中人类巨细胞病毒（HCMV）诱导的早期和晚期肾排斥的长达十年的队列分析。
Viruses. 2024 May 25;16(6):847. doi: 10.3390/v16060847.
3
The pattern of cytomegalovirus replication in post-renal transplant recipients with pre-emptive therapy strategy during the 1 year of post-transplantation.肾移植术后采用抢先治疗策略的患者在移植后1年内巨细胞病毒的复制模式。
Int J Health Sci (Qassim). 2023 Sep-Oct;17(5):39-44.
4
Long-term CMV monitoring and chronic rejection in renal transplant recipients.肾移植受者中 CMV 的长期监测与慢性排斥反应。
Front Cell Infect Microbiol. 2023 Jun 13;13:1190794. doi: 10.3389/fcimb.2023.1190794. eCollection 2023.
5
CMV specific T cell immune response in hepatitis C negative kidney transplant recipients receiving transplant from hepatitis C viremic donors and hepatitis C aviremic donors.丙型肝炎病毒阴性肾移植受者接受丙型肝炎病毒血症供体和丙型肝炎病毒血症供体移植后的 CMV 特异性 T 细胞免疫反应。
Ren Fail. 2022 Dec;44(1):831-841. doi: 10.1080/0886022X.2022.2072744.
6
Assessment of Risk Factors and Outcome of Early Versus Late Cytomegalovirus Infection Infection in Living-related D+/R + Renal Allograft Recipients.活体亲属供肾D+/R+肾移植受者中早期与晚期巨细胞病毒感染的危险因素及结局评估
Indian J Nephrol. 2022 Jan-Feb;32(1):47-53. doi: 10.4103/ijn.IJN_463_20. Epub 2021 Mar 27.
7
Cytomegalovirus Infection after Renal Transplantation: Occurrence, Clinical Features, and the Cutoff for Antigenemia in a University Hospital in Brazil.巴西一家大学医院肾移植后的巨细胞病毒感染：发生率、临床特征及抗原血症的临界值
Infect Chemother. 2017 Dec;49(4):255-261. doi: 10.3947/ic.2017.49.4.255.
8
Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience.抗病毒预防时代肾移植受者的巨细胞病毒血症与死亡率。西澳大利亚经验教训。
BMC Infect Dis. 2017 Jul 17;17(1):501. doi: 10.1186/s12879-017-2599-y.
9
Very-late-onset cytomegalovirus disease: a case-report and review of the literature.极晚发巨细胞病毒病：一例病例报告及文献复习
BMC Res Notes. 2017 Jun 13;10(1):210. doi: 10.1186/s13104-017-2532-x.
10
IL-23 plasma level is strongly associated with CMV status and reactivation of CMV in renal transplant recipients.白细胞介素-23血浆水平与肾移植受者的巨细胞病毒状态及巨细胞病毒再激活密切相关。
BMC Immunol. 2016 Oct 3;17(1):35. doi: 10.1186/s12865-016-0175-7.
本文引用的文献
1
Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation.迟发性原发性巨细胞病毒病与肾移植后同种异体移植失败及死亡风险
Clin Infect Dis. 2008 Mar 15;46(6):840-6. doi: 10.1086/528718.
2
Delayed-onset primary cytomegalovirus disease after liver transplantation.肝移植术后迟发性原发性巨细胞病毒病
Liver Transpl. 2007 Dec;13(12):1703-9. doi: 10.1002/lt.21280.
3
Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation.伐昔洛韦预防与抢先使用缬更昔洛韦治疗预防肾移植后巨细胞病毒病
Am J Transplant. 2008 Jan;8(1):69-77. doi: 10.1111/j.1600-6143.2007.02031.x. Epub 2007 Oct 31.
4
Cytomegalovirus in transplantation - challenging the status quo.移植中的巨细胞病毒——挑战现状
Clin Transplant. 2007 Mar-Apr;21(2):149-58. doi: 10.1111/j.1399-0012.2006.00618.x.
5
Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis.抗病毒预防时代巨细胞病毒对器官移植受者的影响。
Transplantation. 2006 Jun 27;81(12):1645-52. doi: 10.1097/01.tp.0000226071.12562.1a.
6
7
Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis.尽管进行了抗病毒预防，肝移植受者仍发生迟发性巨细胞病毒病。
Transplantation. 2004 Nov 15;78(9):1390-6. doi: 10.1097/01.tp.0000145989.22373.03.
8
Late cytomegalovirus disease with atypical presentation in renal transplant patients: case reports.肾移植患者中表现不典型的晚期巨细胞病毒病：病例报告
Transplant Proc. 2004 Jul-Aug;36(6):1841-3. doi: 10.1016/j.transproceed.2004.07.017.
9
Evolution of immunosuppression at the University of Minnesota.明尼苏达大学免疫抑制的发展历程。
Transplant Proc. 2004 Mar;36(2 Suppl):64S-70S. doi: 10.1016/j.transproceed.2004.01.062.
10
Late cytomegalovirus disease following liver transplantation.肝移植术后晚期巨细胞病毒病
Transpl Int. 2003 Dec;16(12):861-5. doi: 10.1007/s00147-003-0643-x. Epub 2003 Aug 5.
Zotero 插件